Takeda Pharmaceutical Company Limited Revenue | TAK

Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.

Traditionally defined as follows:
Revenue = Price * Quantity of products

Revenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.^[1]

This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.

Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.

Annual Revenue Takeda Pharmaceutical Company Limited

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
4.58 T	4.26 T	4.03 T	3.57 T	3.2 T	3.29 T	2.1 T	1.77 T	1.73 T	1.81 T	1.78 T	1.69 T	1.56 T	1.51 T	1.42 T

All numbers in JPY currency

Indicator range from annual reports

Maximum	Minimum	Average
4.58 T	1.42 T	2.55 T

Quarterly Revenue Takeda Pharmaceutical Company Limited

2025-Q4	2025-Q1	2024-Q4	2024-Q1	2023-Q4	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
-	4.58 T	-	4.26 T	-	4.03 T	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in JPY currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
4.58 T	4.03 T	4.29 T

References

Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).

Revenue of other stocks in the Biotechnology industry

Issuer	Revenue	Price	% 24h	Market Cap	Country
InflaRx N.V. IFRX	29.3 K	$ 1.68	0.58 %	$ 113 M	Germany
Immutep Limited IMMP	10.3 M	$ 4.27	0.46 %	$ 6.22 B	Australia
Immunome IMNM	6.94 M	$ 21.17	1.29 %	$ 1.85 B	USA
Immuron Limited IMRN	7.29 M	$ 1.07	0.46 %	$ 247 M	Australia
Innate Pharma S.A. IPHA	9 M	$ 1.58	1.28 %	$ 142 M	France
Incyte Corporation INCY	5.14 B	$ 114.13	0.06 %	$ 22.3 B	USA
InMed Pharmaceuticals INM	4.94 M	$ 1.33	0.01 %	$ 5.54 M	Canada
INmune Bio INMB	50 K	$ 1.94	0.52 %	$ 48 M	USA
Inovio Pharmaceuticals INO	65.3 K	$ 1.15	2.05 %	$ 53.9 M	USA
Insmed Incorporated INSM	606 M	$ 103.83	2.33 %	$ 20.7 B	USA
Innoviva INVA	411 M	$ 20.64	0.68 %	$ 1.39 B	USA
Iovance Biotherapeutics IOVA	264 M	$ 14.15	0.63 %	$ 5.06 M	USA
Ironwood Pharmaceuticals IRWD	47.7 M	$ 3.65	0.27 %	$ 591 M	USA
Inventiva S.A. IVA	9.2 M	$ 3.48	2.89 %	$ 208 M	France
Jaguar Health JAGX	11.5 M	$ 4.73	29.23 %	$ 11 M	USA
Jazz Pharmaceuticals plc JAZZ	4.27 B	$ 236.04	0.16 %	$ 14.4 B	Irlanda
Johnson & Johnson JNJ	94.2 B	$ 252.93	0.03 %	$ 609 B	USA
Kala Pharmaceuticals KALA	3.89 M	$ 0.36	0.86 %	$ 2.93 M	USA
Kiniksa Pharmaceuticals, Ltd. KNSA	678 M	$ 76.31	0.69 %	$ 5.66 B	USA
Karyopharm Therapeutics KPTI	146 M	$ 0.67	1.51 %	$ 7.33 K	USA
Keros Therapeutics KROS	244 M	$ 11.52	1.41 %	$ 429 M	USA
Krystal Biotech KRYS	389 M	$ 334.85	3.9 %	$ 9.69 B	USA
Kura Oncology KURA	67.5 M	$ 10.62	0.09 %	$ 931 M	USA
Kymera Therapeutics KYMR	39.2 M	$ 109.85	2.29 %	$ 9.28 B	USA
Kazia Therapeutics Limited KZIA	42 K	$ 9.35	0.86 %	$ 143 M	Australia
Lineage Cell Therapeutics LCTX	14.6 M	$ 0.93	2.73 %	$ 214 M	USA
Legend Biotech Corporation LEGN	627 M	$ 18.77	1.1 %	$ 6.92 B	USA
Ligand Pharmaceuticals Incorporated LGND	268 M	$ 306.77	1.26 %	$ 5.93 B	USA
Longeveron LGVN	1.2 M	$ 2.51	0.39 %	$ 44.1 B	USA
Eli Lilly and Company LLY	65.2 B	$ 1 143.12	0.02 %	$ 1.03 T	USA
Lipocine LPCN	1.98 M	$ 2.07	0.98 %	$ 11.3 M	USA
Liquidia Corporation LQDA	158 M	$ 27.64	2.32 %	$ 2.38 B	USA
Lexicon Pharmaceuticals LXRX	49.8 M	$ 1.74	0.82 %	$ 632 M	USA
Seres Therapeutics MCRB	789 K	$ 2.85	0.34 %	$ 25.2 M	USA
Madrigal Pharmaceuticals MDGL	958 M	$ 493.62	0.1 %	$ 11.1 B	USA
MediWound Ltd. MDWD	21.8 M	$ 13.51	0.22 %	$ 368 M	Israel
Mesoblast Limited MESO	17.2 M	$ 14.22	0.99 %	$ 17.2 B	Australia
MacroGenics MGNX	150 M	$ 3.77	5.31 %	$ 238 M	USA
MeiraGTx Holdings plc MGTX	81.4 M	$ 10.92	1.2 %	$ 878 M	USA
Mirum Pharmaceuticals MIRM	521 M	$ 81.43	0.07 %	$ 4.09 B	USA
MannKind Corporation MNKD	349 M	$ 3.82	0.53 %	$ 1.17 B	USA